Researcher

Biography

Brooke completed her PhD at Monash University within the Biomedicine Discovery Institute (BDI) under the supervision of Professor Gail Risbridger in early 2019. During her candidature she studied tumour-stroma interactions in localised prostate cancer using tissue engineering and quantitative mass spectrometry (MS)-based proteomics. Brooke is now a post-doctoral Research Officer at the Garvan Institute of Medical Research, where she is...view more

Brooke completed her PhD at Monash University within the Biomedicine Discovery Institute (BDI) under the supervision of Professor Gail Risbridger in early 2019. During her candidature she studied tumour-stroma interactions in localised prostate cancer using tissue engineering and quantitative mass spectrometry (MS)-based proteomics. Brooke is now a post-doctoral Research Officer at the Garvan Institute of Medical Research, where she is investigating novel stromal targets in pancreatic cancer under the supervision of Professor Paul Timpson. She is using a range of cutting-edge techniques such as patient-derived xenografting (PDX), LC-MS/MS, MALDI imaging and advanced microscopy to study the stroma of both murine and human pancreatic tumours. Brooke is a Conjoint Associate Lecturer in the Faulty of Medicine at UNSW.


My Grants

2020 – 2021    Sydney Catalyst Seed Funding Grant - CIA Brooke Pereira. Dual targeting of stromal and immunological aberrations in pancreatic cancer by combining perlecan inhibition with immunotherapy. ($50,000 AUD)


My Qualifications

PhD - 2019 - Monash University Australia
BS/BEng (Hons) - 2013 - Monash University Australia


My Awards

Awards/Honours

  • 2018 Lorne Cancer Conference Poster Prize – 1 of 6 awarded
  • 2017 EACR Image of the Month – “3D melt electrospun scaffold model of the human prostate tumour microenvironment” http://magazine.eacr.org/eacr-image-of-the-month-october-2016-2017/4/
  • 2016 World Biomaterials Congress (WBC) Trainee Award – 1 of 45 recipients worldwide
  • 2014 ASMR Campion-Ma-Playoust Memorial Award – Best Presentation at the Australian Health and Medical Research Congress
  • 2014 Department of Education Research Training Program (RTP) PhD Stipend
  • 2013 Monash Summer Research Scholarship – Australian Centre of Blood Diseases (ACBD)

Travel Grants

  • 2020 Matrix Biology & Matrix Biology Plus Award
  • 2017 ESA Postgraduate Student Travel Grant
  • 2017 ASBTE Postgraduate Student Travel Grant
  • 2016 Monash University Postgraduate Travel Grant Award
  • 2016 ASBTE Postgraduate Student Travel Grant
  • 2015 Monash Institute for Medical Engineering (MIME) Travel Grant
  • 2014 Justus Liebig University (JLU) Postgraduate Student Travel Grant

My Research Activities

Journal Articles (Published)

  1. SHARBEEN, G., MCCARROLL, J. A., AKERMAN, A., KOPECKY, C., YOUKHANA, J., KOKKINOS, J., HOLST, J., BOYER, C., ERKAN, M., GOLDSTEIN, D., TIMPSON, P., COX, T. R., PEREIRA, B. A., CHITTY, J. L., FEY, S. K., NAJUMUDEEN, A. K., CAMPBELL, A. D., SANSOM, O. J., IGNACIO, R. M. C., NAIM, S., LIU, J., RUSSIA, N., LEE, J., CHOU, A., JOHNS, A., GILL, A. J., GONZALES-ALOY, E., GEBSKI, V., GUAN, Y. F., PAJIC, M., TURNER, N., APTE, M. V., DAVIS, T. P., MORTON, J. P., HAGHIGHI, K. S., KASPARIAN, J., MCLEAN, B. J., SETARGEW, Y. F. I., APGI, A. P. C. G. I. & PHILLIPS, P. A. 2021. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Research, canres.2496. A Novel Metabolism-Targeted Nanomedicine Inhibits Pancreatic Tumour Growth and Remodels the Pancreatic Tumour Stroma. (2021) Cancer Research IF: 9.130

 

  1. TENG, L. K. H., PEREIRA, B. A., KEERTHIKUMAR, S., HUANG, C., NIRANJAN, B., LEE, S. N., RICHARDS, M., SCHITTENHELM, R. B., FURIC, L., GOODE, D. L., LAWRENCE, M. G., TAYLOR, R. A., ELLEM, S. J., RISBRIDGER, G. P.* & LISTER, N. L.* 2021. Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment. 13, 1237. (* contributed equally) (2021) Cancers IF: 6.126 (Second Author)

 

  1. KOKKINOS, J., SHARBEEN, G., HAGHIGHI, K. S., IGNACIO, R. M. C., KOPECKY, C., GONZALES-ALOY, E., YOUKHANA, J., TIMPSON, P., PEREIRA, B. A., RITCHIE, S., PANDZIC, E., BOYER, C., DAVIS, T. P., BUTLER, L. M., GOLDSTEIN, D., MCCARROLL, J. A. & PHILLIPS, P. A. Ex vivo culture of intact human patient derived pancreatic tumour tissue. 11, 1944. (2021) Scientific Reports IF: 4.120.

 

  1. RITCHIE, S., REED, D. A., PEREIRA, B. A*. & TIMPSON, P*. The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. 10:(4). (* contributed equally) (2021) Faculty Reviews IF: 2.640 (Commissioned, Co-Corresponding Author).

 

  1. WU, S. Z., RODEN, D. L., WANG, C., HOLLIDAY, H., HARVEY, K., CAZET, A. S., MURPHY, K. J., PEREIRA, B.A., AL-ERYANI, G., BARTONICEK, N., HOU, R., TORPY, J. R., JUNANKAR, S., CHAN, C.-L., LAM, C. E., HUI, M. N., GLUCH, L., BEITH, J., PARKER, A., ROBBINS, E., SEGARA, D., MAK, C., COOPER, C., WARRIER, S., FORREST, A., POWELL, J., O'TOOLE, S., COX, T. R., TIMPSON, P., LIM, E., LIU, X. S. & SWARBRICK, A. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. 39, e104063. (2020) The EMBO Journal IF: 11.200.

 

  1. LAWRENCE, M. G., PIDSLEY, R., NIRANJAN, B., PAPARGIRIS, M., PEREIRA, B. A., RICHARDS, M., TENG, L., NORDEN, S., RYAN, A., FRYDENBERG, M., STIRZAKER, C., TAYLOR, R. A., RISBRIDGER, G. P. & CLARK, S. J. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. 12, 48 (2020) Clinical Epigenetics IF: 5.496

 

  1. RITCHIE, S., PEREIRA, B. A., VENNIN, C. & TIMPSON, P. 2020. Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation. 24, 171-174 (2020) Expert Opinion in Therapeutic Targets IF: 4.598

 

  1. PEREIRA, B. A.*, VENNIN, C.*, PAPANICOLAOU, M., CHAMBERS, C. R., HERRMANN, D., MORTON, J. P., COX, T. R. & TIMPSON, P. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. 5, 724-741. (* contributed equally) (2019) Trends in Cancer IF: 8.884 (Co-First Author)

 

  1. NGUYEN, E. V.^, PEREIRA, B. A.^, LAWRENCE, M. G., MA, X., REBELLO, R. J., CHAN, H., NIRANJAN, B., WU, Y., ELLEM, S., GUAN, X., WU, J., SKHINAS, J. N., COX, T. R., RISBRIDGER, G. P., TAYLOR, R. A.*, LISTER, N. L.* & DALY, R. J.* Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment. 18, 1410-1427. (^,* contributed equally) (2019) Molecular & Cellular Proteomics IF: 6.540 (Co-First Author)

 

  1. PEREIRA, B. A., LISTER, N. L., HASHIMOTO, K., TENG, L., FLANDES-IPARRAGUIRRE, M., EDER, A., SANCHEZ-HERRERO, A., NIRANJAN, B., Melbourne Urological Research Alliance (MURAL), FRYDENBERG, M., PAPARGIRIS, M.M., LAWRENCE, M.G., TAYLOR, R.A., HUTMACHER, D.W., ELLEM, S.J.*, RISBRIDGER, G.P.*, DE-JUAN-PARDO, E.M.*  Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro. 197, 72-85 (* contributed equally) (2019) Biomaterials IF: 10.237 (First Author)

 

  1. PEREIRA, B. A., LISTER, N. L., DE-JUAN-PARDO, E. M., RISBRIDGER, G. P. & ELLEM, S. J. 5.17 Three-dimensional bioengineered cancer models. (2017) Comprehensive Biomaterials (2nd Edition) (Commissioned, First Author)

 

  1. HUTMACHER, D. W., HOLZAPFEL, B. M., DE-JUAN-PARDO, E. M., PEREIRA, B. A., ELLEM, S. J., LOESSNER, D. & RISBRIDGER, G. P. 2015. Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance. 35, 127-32. Current Opinion in Biotechnology, IF: 8.314

 

  1. KOLODZIEJCZYK, B., WINTHER-JENSEN, O., PEREIRA, B. A., NAIR, S. S. & WINTHER-JENSEN, B. 2015. Patterning of conducting layers on breathable substrates using laser engraving for gas sensors. 132. (2015) Journal of Applied Polymer Science IF: 1.866

 

 

Journal Articles (*Published as APGI Consortium Member)

  1. LAKIS, V., LAWLOR, R. T., NEWELL, F., PATCH, A.-M., MAFFICINI, A., SADANANDAM, A., KOUFARIOTIS, L. T., JOHNSTON, R. L., LEONARD, C., WOOD, S., RUSEV, B., CORBO, V., LUCHINI, C., CINGARLINI, S., LANDONI, L., SALVIA, R., MILELLA, M., CHANG, D., BAILEY, P., JAMIESON, N. B., DUTHIE, F., GINGRAS, M.-C., MUZNY, D. M., WHEELER, D. A., GIBBS, R. A., MILIONE, M., Australian Pancreatic Cancer Genome (APGI)*, ARC-Net, PEDERZOLI, P., SAMRA, J.S., GILL, A.J., JOHNS A.L., PEARSON, J.V., BIANKIN, A.V., GRIMMOND, S.M., WADDELL N, NONES K & SCARPA A. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. 4, 155. (2021) Communications Biology IF: 2.150.

 

  1. DREYER, S. B., PINESE, M., JAMIESON, N. B., SCARLETT, C. J., COLVIN, E. K., PAJIC, M., JOHNS, A. L., HUMPHRIS, J. L., WU, J., COWLEY, M. J., CHOU, A., NAGRIAL, A. M., CHANTRILL, L., CHIN, V. T., JONES, M. D., MORAN-JONES, K., CARTER, C. R., DICKSON, E. J., SAMRA, J. S., MERRETT, N. D., GILL, A. J., KENCH, J. G., DUTHIE, F., MILLER, D. K., COOKE, S., AUST, D., KNÖSEL, T., RÜMMELE, P., GRÜTZMANN, R., PILARSKY, C., NGUYEN, N. Q., MUSGROVE, E. A., BAILEY, P. J., MCKAY, C. J., BIANKIN, A. V., CHANG, D. K., Australian Pancreatic Cancer Genome (APGI)* & Glasgow Precision Oncology. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. 272, 366-376. (2020) Annals of Surgery IF: 9.203.

 

  1. KOKKINOS, J., IGNACIO, R. M. C., SHARBEEN, G., BOYER, C., GONZALES-ALOY, E., GOLDSTEIN, D., MCCARROLL, J. A., PHILLIPS, P. A. & Australian Pancreatic Cancer Genome (APGI)* Targeting the Undruggable in pancreatic Cancer using Nano-based gene silencing drugs. 240, 119742. (2020) Biomaterials IF: 10.250.

 

  1. CASTILLO, L., YOUNG, A. I. J., MAWSON, A., SCHAFRANEK, P., STEINMANN, A. M., NESSEM, D., PARKIN, A., JOHNS, A., CHOU, A., LAW, A. M. K., LUCAS, M. C., MURPHY, K. J., DENG, N., GALLEGO-ORTEGA, D., CALDON, C. E., TIMPSON, P., PAJIC, M., ORMANDY, C. J., OAKES, S. R. & Australian Pancreatic Cancer Genome (APGI)*. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. 39, 1821-1829. (2019) Oncogene IF: 6.854.

 

  1. VENNIN, C., MELENEC, P., ROUET, R., NOBIS, M., CAZET, A. S., MURPHY, K. J., HERRMANN, D., REED, D. A., LUCAS, M. C., WARREN, S. C., ELGUNDI, Z., PINESE, M., KALNA, G., RODEN, D., SAMUEL, M., ZARATZIAN, A., GREY, S. T., DA SILVA, A., LEUNG, W., Australian Pancreatic Cancer Genome (APGI)*, MATHIVANAN, S., WANG, Y., BRAITHWAITE, A. W., CHRIST, D., BENDA, A., PARKIN, A., PHILLIPS, P. A., WHITELOCK, J. M., GILL, A. J., SANSOM, O. J., CROUCHER, D. R., PARKER, B. L., PAJIC, M., MORTON, J. P., COX, T. R. & TIMPSON, P. 2019. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. 10, 3637. (2019) Nature Communications IF: 11.880.

 

View less

Location

Medicine & Health

Contact

ORCID as entered in ROS

orcid_icon https://orcid.org/0000-0003-3513-1214

UNSW Sydney NSW 2052 Australia Telephone +61 2 93851000
Authorised by Deputy Vice-Chancellor (Research)
UNSW CRICOS Provider Code: 00098G ABN: 57 195 873 179

Join the conversation